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Background: The US Federal and Drug Administration (FDA) recently revised statin drug labels to include the
information that increases in fasting serum glucose and glycated haemoglobin levels have been reported with the
use of statins. Yet in a survey, 87% of the doctors stated that they had never or infrequently observed increases in
glucose or HbA1c levels in patients on statin. In this study we would like to determine the association between the
use of statins and glycaemic control in a retrospective cohort of patients with hypertension.
Methods: A retrospective review of 1060 medical records of patients with hypertension at a primary care clinic was
conducted. These records were selected using systematic random sampling (1:4). Data on patient socio-demographic
factors; clinical profile; investigation results and prescribed medications were collected. Independent t-test was used for
continuous variables while Pearson’s χ2 test was used for categorical variables. Logistic regression was done to adjust
for confounders.
Results: 810 (76.4%) patients with hypertension were on statins, out of which 792 (97.8%) were taking simvastatin
10 mg or 20 mg daily. Analysis of the whole group regardless of diabetes status showed that the statin user
group had higher HbA1c and fasting blood glucose values. The difference in HbA1c levels remained significant
(adjusted OR = 1.290, p = 0.044, 95% CI 1.006, 1.654) after adjustment for diabetes, diabetic medication and fasting
blood glucose. In the study population who had diabetes, statin users again had significantly higher HbA1c level
compared to statin non-users. This difference remained significant (adjusted OR 1.208, p = 0.037, 95% CI 1.012,
1.441) after adjustment for age and diabetic medications.
Conclusions: Statins use is associated with increased HbA1c levels among hypertensive patients and hypertensive
patients with diabetes. Clinicians managing hypertensive patients on statins should consider monitoring the HbA1c
level and ensure that those with diabetes have their hyperglycaemia kept under control.
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In February 2012, the US Federal and Drug Administra-
tion (FDA) revised statin drug labels to include the in-
formation that increases in fasting serum glucose and
glycated haemoglobin levels have been reported with the
use of statins [1]. The changes were based on evidence* Correspondence: khooem@um.edu.my
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studies [4-6]. Statin therapy was found to be associated
with an increase in the incidence of diabetes and wors-
ening glycaemic control. This association is worrying be-
cause diabetes doubles the risk of cardiovascular disease
and cardiovascular deaths account for about 50% of deaths
in people with diabetes [7]. Poor glycaemic control also in-
creases the risk of cardiovascular outcomes. The United
Kingdom Prospective Diabetes Study (UKPDS) trial showed
that reduction in glycated haemoglobin by 1% wasd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Liew et al. Diabetology & Metabolic Syndrome 2014, 6:53 Page 2 of 5
http://www.dmsjournal.com/content/6/1/53associated with a 21% decrease in the risk of any end point
or death related to diabetes [8].
Studies have also shown that statins worsened gly-
caemic control in patients with diabetes [9,10]. Yet in a
statin survey, 87% of the doctors stated that they had
never or infrequently observed increases in glucose or
HbA1c levels in patients on statin [11]. This study aimed
to determine the association between the use of statins
and glycaemic control in a retrospective cohort of pa-
tients with hypertension.Table 1 Types of statins and dosages prescribed in study
population
Type of statin prescribed (n = 810) Dosage (mg) n (%)
Simvastatin (n = 792) 5.0 1 (0.1)Methods
A retrospective review of medical records was conducted
between January and May 2012 at a primary care clinic
in a tertiary teaching hospital in Malaysia. Inclusion cri-
teria were 1) patient with hypertension above the age of
18 years, 2) patient had been followed up for at least one
year for hypertension at the clinic, and 3) patient who
attended follow-up appointment within the study period.
Hypertension was defined as a diagnosis of hypertension
as stated in medical records or was on antihypertensive
medication. Approximately 4,000 patients with hyper-
tension attended their follow-up appointments during
the study period. Records were selected using the sys-
tematic random sampling (1:4) method, giving a total of
1060 records.
An electronic self-designed data collection form was used
to collect the following data: patient socio-demographic fac-
tors; clinical profile; investigation results and prescribed
medications. Data were collected by two trained research
assistants. The most recent medication list and investigation
results were obtained from patient records and verified with
the hospital’s electronic record system. Diabetes mellitus
was defined as a documentation of the diagnosis in the
medical record or patients with a fasting blood glucose of
7 mmol/L and above or those who were prescribed medica-









Pravastatin (n = 4) 20.0 3 (75.0)
40.0 1 (25.0)
Rosuvastatin (n = 2) 10.0 1 (50.0)
20.0 1 (50.0)Data analyses
All data was analysed using the Statistical Package for
Social Sciences (SPSS) version 18 (Chicago, Illinois, USA).
Continuous data were expressed as mean ± standard devi-
ation (SD). Categorical variables were expressed as absolute
(number) and relative frequencies (percentage). Independ-
ent t-test was used for comparison of continuous variables
while Pearson’s χ2 test was used for comparison of categor-
ical variables.
All factors that were significantly associated with statin
use in the bivariate analysis, or contributed to the level
of diabetic control, were entered into a logistic regres-
sion model. A p-value of <0.05 was considered statisti-
cally significant.Ethical approval
Ethical approval for this study was obtained from the
University of Malaya Medical Ethics Committee (Reference
number: 890.14). Data were anonymised and patient confi-
dentiality was maintained.
Results
Table 1 shows the types of statins and dosages pre-
scribed in our study population: 810 (76.4%) patients
with hypertension were on statins, out of which 792
(97.8%) were taking simvastatin 10 mg or 20 mg daily.
Table 2 shows the results of the entire study popula-
tion regardless of their diabetes status. A significantly
greater number of hypertensive patients who used sta-
tins were diabetics (51.2% vs. 36.8%) and were on dia-
betic medications (48.3% vs. 30.4%) compared with
non-users. Statin users had higher HbA1c and fasting
blood glucose (FBG) values, compared to non-users.
The difference in HbA1c levels remained significant
(adjusted OR = 1.290, p = 0.044, 95% CI 1.006, 1.654)
after adjusting for diabetes, diabetic medications and
FBG. The association between FBG and statin use was
not significant after adjustment.
Table 3 shows the results of the analysis on two sub-
groups of the study population: 1) hypertensive patients
with diabetes, and 2) hypertensive patients without dia-
betes. In the group of hypertensive patients with dia-
betes, statin users had significantly higher HbA1c levels
compared to statin non-users. This was despite the sig-
nificantly higher use of diabetic medications in the statin
user group. Among the hypertensive patients with dia-
betes, 92.1% were on diabetic medications. The diabetic
medications taken were metformin (n = 422, 83.2%),
Table 2 Profiles of hypertensive patients who were statins users versus non-users
Statin users (n = 810) Statin non users (n = 250) P-value 95% CI
Mean (SD) age (years) 62.23 (9.81) 61.16 (12.16) 0.205* −2.725, 0.586
DM [n(%)] 415 (81.9) 92 (18.1) <0.001**
Non DM [n(%)] 395 (71.4) 158 (28.6)
On DM medication [n(%)] 391 (83.7) 76 (16.3) <0.001**
Not on DM medication [n(%)] 419 (70.7) 174 (29.3)
HbA1c# n = 444 n = 110
Mean IFCC unit (SD) mmol/mol 59 (19) 52 (16) 0.001* −10.378, −2.801
Mean NGSP unit (SD) % 7.5 (1.7) 6.9 (1.5) 0.001* −0.942, −0.247
FBG# n = 746 n = 219
Mean (SD) mmol/L 6.63 (2.49) 6.05 (1.93) <0.001* −0.886, −0.261
DM=Diabetes mellitus; HbA1c=Glycated haemoglobin; FBG=Fasting blood glucose.
IFCC = International Federation of Clinical Chemistry; NGSP = National Glycohemoglobin Standardization Program.
#Most recent result in the past one year.
*Independent sample t-test.
**Chi-square test.
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gliptins (n = 2, 0.4%) and insulin (n = 75, 14.8%). The dif-
ference in HbA1c levels remained significant after ad-
justment for age and diabetic medication (adjusted OR
1.208, p = 0.037, 95% CI 1.012, 1.441). There was no dif-
ference in the FBG level, HDL levels, age, BMI, gender,
ethnicity, diuretics and beta blockers use, and duration
of diabetes between statins users and non-users in the
study population who had diabetes. Triglyceride levels
were significantly lower in statin users compared to
non-users in those with diabetes.
In the group of hypertensive patients without diabetes,
age and FBG values were significantly higher among statin
users compared with non-users. However, after adjustment
for age and FBG, both factors became non-significant.
There was no significant association found between HbA1c
levels and statin use. The number of patients with HbA1c
results was small in this group (Table 3).
Discussion
There are two key findings from this study – 1) patients
with hypertension and those with coexisting diabetes
who used statins have significantly higher HbA1c levels
compared to those not using statins and 2) the poor gly-
caemic control is not reflected by fasting glucose levels.
Higher HbA1c levels in statin users for the overall
study population of hypertensive patients with and with-
out diabetes suggests that statins affect glycaemic con-
trol not just in patients with diabetes but in hypertensive
patients without diabetes as well. The association between
HbA1c and statin remained significant after adjustment
for possible confounders. Although this association was
not significant in subgroup analysis for the non-diabetics,
this could possibly be due to the small number of patients
with HbA1c results in this subgroup. There was asimilar trend for fasting blood glucose levels in non-
diabetics but this was non-significant after adjustment
for confounders. Poor glycaemic control with statin use
could increase cardiovascular risk in the long-term in
patients with hypertension on statins. Therefore regular
monitoring of glycaemic control is important in this
group of patients.
Fasting blood glucose level was higher in patients with
diabetes who were on statins, but this did not reach sig-
nificance. A significantly greater proportion of diabetics
on statins were prescribed diabetic medications com-
pared with diabetics not on statins. It is a possibility that
poorer glycaemic control in the diabetics on statin group
necessitates the use of medication i.e. improving fasting
blood glucose control but not improving overall gly-
caemic control as reflected by the higher HbA1c levels.
Antihypertensive medications such as diuretics and
beta blockers as well as diabetes duration could poten-
tially affect glycaemic control. However, the analysis
showed that these antihypertensive agents and the dur-
ation of diabetes were not significantly associated with
statin use in patients with diabetes. As expected, trigly-
ceride levels were significantly lower in statin users com-
pared to non-users in those with diabetes.
Most of the previous studies which have shown similar
findings were conducted in clinical trial participants,
which had strict controlled settings. This is a retrospect-
ive cohort, which could only show association and not
causation. It is possible that the association seen be-
tween statins and hyperglycaemia may be due to the
clustering of hyperlipidaemia, hypertension and glucose
intolerance, which are known features of metabolic syn-
drome. Nevertheless, the association was also seen in pa-
tients who did not have diabetes although this was not
significant after adjustment. However, it has highlighted
Table 3 Comparison of socio-demographic factors and glucose control of hypertensive patients with and without
diabetes who were statins users or non-users
Hypertensive patients with DM (n = 507) Hypertensive patients without DM (n = 553)
Statin users Statin non users P value (95% CI) Statin users Statin non users P value (95% CI)
n = 415 n = 92 n = 396 n = 157
Age (years) Mean (SD) 61.71 (9.29) 62.17 (12.02) 0.728* (−2.176, 3.107) 62.80 (10.30) 60.52 (12.23) 0.039* (−4.463, −0.111)
Gender n (%)
Men 176 (84.6) 32 (15.4) 0.178** 155 (70.8) 64 (29.2) 0.725**
Women 239 (79.9) 60 (20.1) 241 (72.2) 93 (27.8)
Ethnicity n (%)
Malay 137 (83.5) 27 (16.5) 0.737** 116 (73.0) 43 (27.0) 0.808**
Chinese 160 (80.4) 39 (19.6) 220 (71.0) 90 (29.0)
Indian 115 (81.6) 26 (18.4) 54 (70.1) 23 (29.9)
Others 3 (100.0) 0 (0.0) 6 (85.7) 1 (14.3)
Duration of diabetes (years) n = 406 n = 84
Mean (SD) 8.169 (6.556) 7.020 (6.255) 0.141*
HbA1c# n = 372 n = 77 n = 72 n = 33
Mean IFCC unit (SD) mmol/mol 62 (19) 57 (17) 0.030* (−9.610, −0.494) 44 (5) 42 (6) 0.082* (−3.972, 0.242)
Mean NGSP unit (SD)% 7.8 (1.7) 7.3 (1.6) 0.034* (−0.871, −0.034) 6.1 (0.4) 6.0 (0.5) 0.089* (−0.363, 0.026)
FBG# n = 397 n = 87 n = 350 n = 131
Mean (SD) mmol/L 7.71 (2.98) 7.25 (2.55) 0.179* (−1.142, 0.213) 5.39 (0.53) 5.27 (0.58) 0.029* (−0.231, −0.012)
TG# n = 383 n = 84 n = 361 n = 137
Mean (SD) mmol/L 1.602 (0.737) 1.965 (1.289) 0.014* (0.075, 0.653) 1.416 (0.623) 1.357 (0.628) 0.346* (−0.182, 0.064)
HDL# n = 383 n = 84 n = 361 n = 137
Mean (SD) mmol/L 1.269 (0.317) 1.204 (0.322) 0.092* (−0.140, 0.011) 1.465 (0.420) 1.373 (0.380) 0.026* (−0.173,-0.011)
Body Mass Index n = 232 n = 44 n = 150 n = 58
Mean (SD) Kg/m2 28.02 (5.37) 27.74 (4.70) 0.744* (−1.990, 1.423) 27.44 (4.67) 26.73 (5.35) 0.350* (−2.189, 0.778)
Diabetic medication n (%)
Yes 391 (83.7) 76 (16.3) <0.001**
No 24 (60.0) 16 (40.0)
On diuretic and/or
beta-blocker n (%)
Yes 201 (80.1) 50 (19.9) 0.305** 196 (74.5) 67 (25.5) 0.148**
No 214 (83.6) 42 (16.4) 200 (69.0) 90 (31.0)
DM = Diabetes mellitus; HbA1c = Glycated haemoglobin; FBG = Fasting blood glucose; TG = Triglyceride; HDL = HDL-Cholesterol.
IFCC = International Federation of Clinical Chemistry; NGSP = National Glycohemoglobin Standardization Program.
# Most recent result in the past one year.
*Independent sample t-test.
**Chi-square test.
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patients with diabetes in a ‘real-life’ setting. Doctors may
not have recognised this previously because the fasting
blood glucose levels do not increase significantly and the
effect is lessened by medication. Although there appears
to be a response by prescribers to the poorer glycaemic
control in that the number of diabetes medications was
increased in this group, yet this response was insufficient
to control the higher HbA1c levels.The findings from this observational cohort concur
with trials which indicate that statins are associated with
poorer glycaemic control in patients with diabetes and
hypertension. Statins have been shown to affect glucose
metabolism in multiple ways such as by inhibition of in-
sulin secretion and downregulation of a glucose trans-
porter in adipocytes [12]. Clinicians managing patients
with diabetes should take note of this and ensure that
glycaemic control is managed accordingly.
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Statin use is associated with increased HbA1c levels
among hypertensive patients and hypertensive patients
with diabetes. As the evidence for statin therapy in redu-
cing mortality is much stronger than the evidence to
support glucose lowering therapy, clinicians managing
hypertensive patients with diabetes on statins should not
stop statin use but ensure that hyperglycaemia is kept
under control. For patients with hypertension and using
statins, regular HbA1c monitoring may be useful.
Abbreviation
BMI: Body mass index; DM: Diabetes mellitus; FDA: Food and Drug
Administration; FBG: Fasting blood glucose; HbA1c: Glycated haemoglobin;
IFCC: International Federation of Clinical Chemistry; NGSP: National
Glycohemoglobin Standardization Program; UKPDS: United Kingdom
Prospective Diabetes Study.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
SM, PY and EM drafted the manuscript. All authors participated in the
conception and design of the study. SM, PY, NF and EM performed the
statistical analysis. All authors read and approved the final manuscript.
Acknowledgements
This project was funded by Institute of Research Management and
Monitoring (IPPP) University of Malaya Research Grant (UMRG) RG335/11HTM.
Author details
1Department of Primary Care Medicine, University of Malaya Primary Care
Research Group (UMPCRG), Faculty of Medicine, University of Malaya, Kuala
Lumpur, Malaysia. 2Department of Family Medicine, Universiti Putra Malaysia,
Serdang, Selangor, Malaysia.
Received: 17 December 2013 Accepted: 3 April 2014
Published: 23 April 2014
References
1. U.S. Food and Drug Administration: FDA Drug Safety Communication:
Important Safety Label Changes to Cholesterol-Lowering Statin Drugs.
http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
2. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ,
Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG,
Shepherd J, Willerson JT, Glynn RJ: JUPITER Study Group. Rosuvastatin to
prevent vascular events in men and women with elevated C-reactive
protein. N Engl J Med 2008, 359:2195–2207.
3. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP: High-dose
atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22
substudy. Circulation 2004, 110(Suppl I):S834.
4. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai
SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott
DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM,
Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto
AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, et al: Statins and risk
of incident diabetes: a collaborative meta-analysis of randomized statin
trials. Lancet 2010, 375:735–742.
5. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM:
Statin therapy and risk of developing type 2 diabetes: a meta-analysis.
Diabetes Care 2009, 32:1924–1929.
6. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM,
Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C,
Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y: Statin use and risk of
diabetes mellitus in postmenopausal women in the Women’s Health
Initiative. Arch Intern Med 2012, 172(2):144–152.
7. International Diabetes Federation: IDF Diabetes Atlas. 3rd edition. Brussels:
International Diabetes Federation; 2006.8. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden
D, Turner RC, Holman RR: Association of glycaemia with macrovascular
and microvascular complications of type 2 diabetes (UKPDS 35):
prospective observational study. BMJ 2000, 321:405–412.
9. Simsek S, Schalkwijk CG, Wolffenbuttel BH: Effects of rosuvastatin and
atorvastatin on glycaemic control in type 2 diabetes—the CORALL
study. Diabet Med 2012, 29:628–631.
10. Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A: Influences of
statins on glucose tolerance in patients with type 2 diabetes mellitus.
J Atheroscler Thromb 2006, 13:95–100.
11. O’Riordan M: theheart.org’s statin safety survey draws mixed response.
http://www.medscape.com/viewarticle/791177.
12. Sampson UK, Linton MF, Fazio S: Are statins diabetogenic? Curr Opin
Cardiol 2011, 26(4):342–347.
doi:10.1186/1758-5996-6-53
Cite this article as: Liew et al.: Statins use is associated with poorer
glycaemic control in a cohort of hypertensive patients with diabetes
and without diabetes. Diabetology & Metabolic Syndrome 2014 6:53.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
